Skip to main content
Top
Published in: Cancer Immunology, Immunotherapy 3/2007

01-03-2007 | Original Article

Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population

Authors: Penka N. Nikolova, Graham P. Pawelec, Snejina M. Mihailova, Milena I. Ivanova, Anastassia P. Myhailova, Daniela N. Baltadjieva, Daniela I. Marinova, Svetlomira S. Ivanova, Elissaveta J. Naumova

Published in: Cancer Immunology, Immunotherapy | Issue 3/2007

Login to get access

Abstract

It has been hypothesized that polymorphisms expected to result in functional changes in cytokine genes may influence susceptibility to cancer, including malignant melanoma (MM). Here, we have screened 24 potentially functional polymorphisms in five cytokine genes by PCR-SBT and PCR-SSP methods in 122 MM cell lines derived from Caucasian patients. The polymorphic positions studied were: TNFA −1031, −863, −857, −851, −574, −376, −308, −238, +488; TGFB1 −988, −800, −509, +869, +915, +652, +673, +713, +788; IL10 −1082, −819, −592; IL6 −174; IFNG −333, +874. The frequencies of cytokine genotypes of melanoma tumours were compared with those published for healthy Caucasians. It was found that TNFA −238 GA, TGFB1 −509 CT, −800 GG, IFNG +874 AT, IL6 −174 GG, IL10 −1082 GA genotypes were significantly decreased, while TNFA −238 AA, −857 CC, TGFB1 −509 TT, IFNG +874 AA, IL6 −174 CC, IL10 −1082 AA, −819 TT, −592 AA genotypes were significantly increased, in MM. This suggests that genotypes provisionally associated with low expression of pro-inflammatory and immunomodulatory TNF-α, IFN-γ and IL-6 and anti-inflammatory IL-10 and TGF-β1 could be involved in the mechanisms of cancer progression and escape from immunoserveilance.
Literature
1.
go back to reference el-Far M, Fouda M, Yahya R, el-Baz H (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J Physiol Biochem 6:253–258CrossRef el-Far M, Fouda M, Yahya R, el-Baz H (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J Physiol Biochem 6:253–258CrossRef
2.
go back to reference Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS (2005) An interleukin-10 promoter polymorphism may influence tumour development in renal cell carcinoma. J Urol 173:709–712PubMedCrossRef Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS (2005) An interleukin-10 promoter polymorphism may influence tumour development in renal cell carcinoma. J Urol 173:709–712PubMedCrossRef
3.
go back to reference Howell WM, Calder PC, Grimble RF (2002a) Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 61:447–456CrossRef Howell WM, Calder PC, Grimble RF (2002a) Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 61:447–456CrossRef
4.
go back to reference Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumour necrosis factor in solid tumours: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6:103–107PubMed Ardizzoia A, Lissoni P, Brivio F, Tisi E, Perego MS, Grassi MG, Pittalis S, Crispino S, Barni S, Tancini G (1992) Tumour necrosis factor in solid tumours: increased blood levels in the metastatic disease. J Biol Regul Homeost Agents 6:103–107PubMed
5.
go back to reference Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef
6.
go back to reference Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, Oral HB (2005) Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30:41–45PubMedCrossRef Basturk B, Yavascaoglu I, Vuruskan H, Goral G, Oktay B, Oral HB (2005) Cytokine gene polymorphisms as potential risk and protective factors in renal cell carcinoma. Cytokine 30:41–45PubMedCrossRef
7.
go back to reference Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH, Tsai FJ (2005) CYP17 and tumour necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol 125:96–99PubMedCrossRef Chen WC, Tsai MH, Wan L, Chen WC, Tsai CH, Tsai FJ (2005) CYP17 and tumour necrosis factor-alpha gene polymorphisms are associated with risk of oral cancer in Chinese patients in Taiwan. Acta Otolaryngol 125:96–99PubMedCrossRef
8.
go back to reference Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado JC et al (2005) G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334:588–592PubMedCrossRef Duarte I, Santos A, Sousa H, Catarino R, Pinto D, Matos A, Pereira D, Moutinho J, Canedo P, Machado JC et al (2005) G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer. Biochem Biophys Res Commun 334:588–592PubMedCrossRef
9.
go back to reference Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, Lanas A (2005) No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet 32:299–306PubMedCrossRef Garcia-Gonzalez MA, Savelkoul PH, Benito R, Santolaria S, Crusius JB, Pena AS, Lanas A (2005) No allelic variant associations of the IL-1 and TNF gene polymorphisms in the susceptibility to duodenal ulcer disease. Int J Immunogenet 32:299–306PubMedCrossRef
10.
go back to reference Guo W, Wang N, Li Y, Zhang JH (2005a) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878 Guo W, Wang N, Li Y, Zhang JH (2005a) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878
11.
go back to reference Liu D, O’Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J (2005) Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11:1237–1246PubMed Liu D, O’Day SJ, Yang D, Boasberg P, Milford R, Kristedja T, Groshen S, Weber J (2005) Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 11:1237–1246PubMed
12.
go back to reference Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, Lee JH, Kim JH, Yoo JY. (2005a) Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225:207–214CrossRef Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, Lee JH, Kim JH, Yoo JY. (2005a) Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225:207–214CrossRef
13.
go back to reference Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L et al (2005) Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine 30:293–302PubMedCrossRef Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M, Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L et al (2005) Cytokine gene polymorphisms in gastric cancer patients from two Italian areas at high and low cancer prevalence. Cytokine 30:293–302PubMedCrossRef
14.
go back to reference Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005a) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165 Seifart C, Plagens A, Dempfle A, Clostermann U, Vogelmeier C, von Wichert P, Seifart U (2005a) TNF-alpha, TNF-beta, IL-6, and IL-10 polymorphisms in patients with lung cancer. Dis Markers 21:157–165
15.
go back to reference Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C (2005) Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15:53–60PubMedCrossRef Alonso R, Suarez A, Castro P, Lacave AJ, Gutierrez C (2005) Influence of interleukin-10 genetic polymorphism on survival rates in melanoma patients with advanced disease. Melanoma Res 15:53–60PubMedCrossRef
16.
go back to reference Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25–31PubMedCrossRef Howell WM, Turner SJ, Bateman AC, Theaker JM (2001) IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun 2:25–31PubMedCrossRef
17.
go back to reference Howell WM, Turner SJ, Theaker JM, Bateman AC (2003) Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30:409–414PubMedCrossRef Howell WM, Turner SJ, Theaker JM, Bateman AC (2003) Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet 30:409–414PubMedCrossRef
18.
go back to reference Howell WM, Turner SJ, Collins A, Bateman AC, Theaker JM (2002b) Influence of TNFalpha and LTalpha single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur J Immunogenet 29:17–23CrossRef Howell WM, Turner SJ, Collins A, Bateman AC, Theaker JM (2002b) Influence of TNFalpha and LTalpha single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur J Immunogenet 29:17–23CrossRef
19.
go back to reference Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Luise Rao M, Maier W, Heun R (2000) Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer’s disease risk in a German population. Neurosci Lett 283:109–112PubMedCrossRef Bagli M, Papassotiropoulos A, Knapp M, Jessen F, Luise Rao M, Maier W, Heun R (2000) Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer’s disease risk in a German population. Neurosci Lett 283:109–112PubMedCrossRef
20.
go back to reference Constantinidou N (2003) Genotyping for polymorphisms in cytokine genes EFIS, Immunol Lett 87:1–351CrossRef Constantinidou N (2003) Genotyping for polymorphisms in cytokine genes EFIS, Immunol Lett 87:1–351CrossRef
21.
go back to reference Nancy L, Lucas P, Zachary A, Leffell S (2004) TNF-α, TGF-β, IL-10, IL-6, and INF-γ alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops Part IV. Hum Immunol 65:1413–1419CrossRef Nancy L, Lucas P, Zachary A, Leffell S (2004) TNF-α, TGF-β, IL-10, IL-6, and INF-γ alleles among African Americans and Cuban Americans. Report of the ASHI Minority Workshops Part IV. Hum Immunol 65:1413–1419CrossRef
22.
go back to reference Rasmussen SK, Urhammer SA, Jensen J, Hansen T, Borch-Johnsen K, Pedersen O (2000) The −238 and −308 G–>A polymorphisms of the tumour necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 85:1731–1734PubMedCrossRef Rasmussen SK, Urhammer SA, Jensen J, Hansen T, Borch-Johnsen K, Pedersen O (2000) The −238 and −308 G–>A polymorphisms of the tumour necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J Clin Endocrinol Metab 85:1731–1734PubMedCrossRef
23.
go back to reference Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U, Muller B, Vogelmeier C, von Wichert P (2005b) TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65:93–100CrossRef Seifart C, Dempfle A, Plagens A, Seifart U, Clostermann U, Muller B, Vogelmeier C, von Wichert P (2005b) TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65:93–100CrossRef
24.
go back to reference Spriewald BM, Witzke O, Wassmuth R, Wenzel RR, Arnold ML, Philipp T, Kalden JR (2005) Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s granulomatosis. Ann Rheum Dis 64:457–461PubMedCrossRef Spriewald BM, Witzke O, Wassmuth R, Wenzel RR, Arnold ML, Philipp T, Kalden JR (2005) Distinct tumour necrosis factor alpha, interferon gamma, interleukin 10, and cytotoxic T cell antigen 4 gene polymorphisms in disease occurrence and end stage renal disease in Wegener’s granulomatosis. Ann Rheum Dis 64:457–461PubMedCrossRef
25.
go back to reference Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E, Martin J (1997) Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 49:74–78PubMed Vinasco J, Beraun Y, Nieto A, Fraile A, Mataran L, Pareja E, Martin J (1997) Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 49:74–78PubMed
26.
go back to reference Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Aria JM, Inigo P, Sanz S et al (2003) Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:431–435PubMedCrossRef Xaubet A, Marin-Arguedas A, Lario S, Ancochea J, Morell F, Ruiz-Manzano J, Rodriguez-Becerra E, Rodriguez-Aria JM, Inigo P, Sanz S et al (2003) Transforming growth factor-beta1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 168:431–435PubMedCrossRef
27.
go back to reference Giedraitis V, He B, Hillert L (1999) Mutation screening of the interferon-gamma gene as a candidate for multiple sclwrosis. Eur J Immunogenet 26:257–259PubMedCrossRef Giedraitis V, He B, Hillert L (1999) Mutation screening of the interferon-gamma gene as a candidate for multiple sclwrosis. Eur J Immunogenet 26:257–259PubMedCrossRef
28.
go back to reference Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM (2005) TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 191:969–976PubMedCrossRef Deshpande A, Nolan JP, White PS, Valdez YE, Hunt WC, Peyton CL, Wheeler CM (2005) TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J Infect Dis 191:969–976PubMedCrossRef
29.
go back to reference Jang WH, Yang Y, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH (2001) The −238 tumour necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 166:41–46PubMedCrossRef Jang WH, Yang Y, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH (2001) The −238 tumour necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett 166:41–46PubMedCrossRef
30.
go back to reference Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, Noh DY, Ahn SH, Hirvonen A, Kang D. (2005b) Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155CrossRef Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, Noh DY, Ahn SH, Hirvonen A, Kang D. (2005b) Genetic polymorphisms of TGF-beta1 & TNF-beta and breast cancer risk. Breast Cancer Res Treat 90:149–155CrossRef
31.
go back to reference Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM (1997) High dose tumour necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 79:1129–1137PubMedCrossRef Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, Meller I, Klausner JM (1997) High dose tumour necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a > 90% response rate and limb preservation. Cancer 79:1129–1137PubMedCrossRef
32.
go back to reference Mueller H (1998) Tumour necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 54:1291–1298 PubMedCrossRef Mueller H (1998) Tumour necrosis factor as an antineoplastic agent: pitfalls and promises. Cell Mol Life Sci 54:1291–1298 PubMedCrossRef
33.
go back to reference Mocellin S, Rossi CR, Pilati P, Nitti D (2004) Tumour necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35–53PubMedCrossRef Mocellin S, Rossi CR, Pilati P, Nitti D (2004) Tumour necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev 16:35–53PubMedCrossRef
34.
go back to reference Guo W, Wang N, Li Y, Zhang JH (2005b) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878 Guo W, Wang N, Li Y, Zhang JH (2005b) Polymorphisms in tumour necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118:1870–1878
35.
go back to reference Oh BR, Sasaki M, Perinchery G, Ryu S, Park Y, Carroll P, Dahiya R (2000) Frequent genotype changes at −308, and 488 regions of the tumour necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 163:1584–1587PubMedCrossRef Oh BR, Sasaki M, Perinchery G, Ryu S, Park Y, Carroll P, Dahiya R (2000) Frequent genotype changes at −308, and 488 regions of the tumour necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer. J Urol 163:1584–1587PubMedCrossRef
36.
go back to reference Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumour necrosis factor-alpha gene promoter. Tissue Antigens 52:359–367PubMed Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE (1998) Identification of three new single nucleotide polymorphisms in the human tumour necrosis factor-alpha gene promoter. Tissue Antigens 52:359–367PubMed
37.
go back to reference Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, Maerker-Hermann E, Hoehler T (2000) Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 114:1180–1183PubMedCrossRef Kaluza W, Reuss E, Grossmann S, Hug R, Schopf RE, Galle PR, Maerker-Hermann E, Hoehler T (2000) Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 114:1180–1183PubMedCrossRef
38.
go back to reference Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005) The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res 24:415–421PubMed Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y (2005) The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res 24:415–421PubMed
39.
go back to reference Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214PubMed Skerrett DL, Moore EM, Bernstein DS, Vahdat L (2005) Cytokine genotype polymorphisms in breast carcinoma: associations of TGF-beta1 with relapse. Cancer Invest 23:208–214PubMed
40.
go back to reference Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumour suppression and cancer progression. Nat Genet 29:117–129PubMedCrossRef Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumour suppression and cancer progression. Nat Genet 29:117–129PubMedCrossRef
41.
go back to reference Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570PubMedCrossRef Shin A, Shu XO, Cai Q, Gao YT, Zheng W (2005) Genetic polymorphisms of the transforming growth factor-beta1 gene and breast cancer risk: a possible dual role at different cancer stages. Cancer Epidemiol Biomarkers Prev 14:1567–1570PubMedCrossRef
42.
go back to reference Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77:1492–1494PubMed Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U, Orfanos CE (1998) Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br J Cancer 77:1492–1494PubMed
43.
go back to reference Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Lube RN, Chang-Claude J, Mannermaa A, Kataja V et al (2003) A transforming growth factor beta 1 peptide variant increases secretion in vitro and is associated with increased evidence of invasive breast cancer. Cancer Res 63:2610–2615PubMed Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Lube RN, Chang-Claude J, Mannermaa A, Kataja V et al (2003) A transforming growth factor beta 1 peptide variant increases secretion in vitro and is associated with increased evidence of invasive breast cancer. Cancer Res 63:2610–2615PubMed
44.
go back to reference Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin−10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465–469PubMedCrossRef Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Caselles T, Frias JF, Alvarez-Lopez MR (2002) Interleukin−10, interleukin-6 and interferon-gamma gene polymorphisms in melanoma patients. Melanoma Res 12:465–469PubMedCrossRef
45.
go back to reference Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697–703PubMedCrossRef Huang S, Ullrich SE, Bar-Eli M (1999) Regulation of tumour growth and metastasis by interleukin-10: the melanoma experience. J Interferon Cytokine Res 19:697–703PubMedCrossRef
46.
go back to reference Kundi MZ, Ahmad I, Anjum M (1997) Evaluation of diarrhoea management of health professionals trained at the Diarrhoea Training Unit of Rawalpindi General Hospital. J Pak Med Assoc 47:3–6PubMed Kundi MZ, Ahmad I, Anjum M (1997) Evaluation of diarrhoea management of health professionals trained at the Diarrhoea Training Unit of Rawalpindi General Hospital. J Pak Med Assoc 47:3–6PubMed
47.
go back to reference Ishihara K, Hirano T (2002) Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta 1592:281–296PubMedCrossRef Ishihara K, Hirano T (2002) Molecular basis of the cell specificity of cytokine action. Biochim Biophys Acta 1592:281–296PubMedCrossRef
48.
go back to reference Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721–1726PubMedCrossRef Bachelot T, Ray-Coquard I, Menetrier-Caux C, Rastkha M, Duc A, Blay JY (2003) Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 88:1721–1726PubMedCrossRef
49.
go back to reference Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133–138PubMedCrossRef Belluco C, Nitti D, Frantz M, Toppan P, Basso D, Plebani M, Lise M, Jessup JM (2000) Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer. Ann Surg Oncol 7:133–138PubMedCrossRef
50.
go back to reference Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 164:1038–1042PubMed Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O (1991) Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol. 164:1038–1042PubMed
51.
go back to reference Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumour necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223:113–119PubMedCrossRef Kamali-Sarvestani E, Merat A, Talei AR (2005) Polymorphism in the genes of alpha and beta tumour necrosis factors (TNF-alpha and TNF-beta) and gamma interferon (IFN-gamma) among Iranian women with breast cancer. Cancer Lett 223:113–119PubMedCrossRef
52.
go back to reference Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–10800PubMedCrossRef Nilsson MB, Langley RR, Fidler IJ (2005) Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 65:10794–10800PubMedCrossRef
53.
go back to reference Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753–756PubMedCrossRef Tan D, Wu X, Hou M, Lee SO, Lou W, Wang J, Janarthan B, Nallapareddy S, Trump DL, Gao AC. (2005) Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 174:753–756PubMedCrossRef
54.
go back to reference Basolo F, Fiore L, Fontanini G, Conaldi PG, Calvo S, Falcone V, Toniolo A (1996) Expression of and response to interleukin 6 (IL6) in human mammary tumours. Cancer Res 56:3118–3122PubMed Basolo F, Fiore L, Fontanini G, Conaldi PG, Calvo S, Falcone V, Toniolo A (1996) Expression of and response to interleukin 6 (IL6) in human mammary tumours. Cancer Res 56:3118–3122PubMed
55.
go back to reference Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A (2000) Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumour cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673–5680PubMed Ruiz-Ruiz C, Munoz-Pinedo C, Lopez-Rivas A (2000) Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumour cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res 60:5673–5680PubMed
56.
go back to reference Ozzello L, de Rosa CM, Cantell K, Kauppinen HL, Habif DSr. (1995) Regression of human breast cancer xenografts in response to intralesional treatment with interferons alpha and gamma potentieted by tumour necrosis factor. J. Interferon Cytokine Res 15:839–848PubMedCrossRef Ozzello L, de Rosa CM, Cantell K, Kauppinen HL, Habif DSr. (1995) Regression of human breast cancer xenografts in response to intralesional treatment with interferons alpha and gamma potentieted by tumour necrosis factor. J. Interferon Cytokine Res 15:839–848PubMedCrossRef
57.
go back to reference Bubenik J (2005) MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 51:1–2 Bubenik J (2005) MHC class I down regulation, tumour escape from immune surveillance and design of therapeutic strategies. Folia Biol (Praha) 51:1–2
Metadata
Title
Association of cytokine gene polymorphisms with malignant melanoma in Caucasian population
Authors
Penka N. Nikolova
Graham P. Pawelec
Snejina M. Mihailova
Milena I. Ivanova
Anastassia P. Myhailova
Daniela N. Baltadjieva
Daniela I. Marinova
Svetlomira S. Ivanova
Elissaveta J. Naumova
Publication date
01-03-2007
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 3/2007
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-006-0193-z

Other articles of this Issue 3/2007

Cancer Immunology, Immunotherapy 3/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine